Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Regeneron Pharmaceuticals Price Performance
NASDAQ:REGN opened at $623.90 on Friday. Regeneron Pharmaceuticals has a 52 week low of $538.01 and a 52 week high of $747.42. The company has a quick ratio of 4.39, a current ratio of 5.12 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $67.72 billion, a PE ratio of 12.45, a price-to-earnings-growth ratio of 2.17 and a beta of 0.29. The stock's 50-day moving average price is $596.03 and its 200-day moving average price is $636.26.
Regeneron Pharmaceuticals (NASDAQ:REGN - Get Rating) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 EPS for the quarter, missing analysts' consensus estimates of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The business had revenue of $2.86 billion for the quarter, compared to analyst estimates of $2.80 billion. During the same quarter last year, the business earned $27.97 earnings per share. Regeneron Pharmaceuticals's revenue was down 44.4% on a year-over-year basis. As a group, equities analysts expect that Regeneron Pharmaceuticals will post 35.9 EPS for the current fiscal year.
Analysts Set New Price Targets
REGN has been the topic of several recent research reports. StockNews.com cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Tuesday, July 26th. Jefferies Financial Group cut Regeneron Pharmaceuticals to a "sell" rating and set a $536.00 target price on the stock. in a research report on Friday, June 17th. Cowen increased their target price on Regeneron Pharmaceuticals from $635.00 to $645.00 in a research report on Wednesday, July 20th. Cowen increased their target price on Regeneron Pharmaceuticals to $655.00 in a research report on Tuesday. Finally, Cantor Fitzgerald initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, July 12th. They set a "neutral" rating and a $625.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $698.35.
Insider Buying and Selling
In related news, EVP Neil Stahl sold 23,782 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $612.61, for a total value of $14,569,091.02. Following the sale, the executive vice president now directly owns 52,795 shares in the company, valued at approximately $32,342,744.95. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, EVP Neil Stahl sold 23,782 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $612.61, for a total value of $14,569,091.02. Following the sale, the executive vice president now directly owns 52,795 shares in the company, valued at approximately $32,342,744.95. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Marion Mccourt sold 1,100 shares of the business's stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $587.76, for a total value of $646,536.00. Following the transaction, the executive vice president now owns 19,644 shares in the company, valued at $11,545,957.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,435 shares of company stock worth $31,663,304. Insiders own 8.99% of the company's stock.
